DCx sees potential to build multifunctional ADCs using the same technology Repare used to create its small molecule synthetic lethal therapies.

The firm is studying the combination in the first-line setting for head and neck cancer patients who had a PD-L1 combined positive score of less than 1.

The biotech has nominated MB-111, a drug it's developing as a treatment for elevated triglycerides, as its first clinical development candidate.